Horizon Discovery has launched its reagent platform for CRISPR activation as the latest addition to the company's Edit-R portfolio for CRISPR-Cas9 genome engineering. The new Edit-R CRISPRa offering provides researchers interested in gain-of-function studies with a two-component system for drug discovery, disease modeling, or pathway analysis. The system is available in lentiviral and synthetic formats and is well-suited for robust overexpression in virtually any cell system, Horizon said. This format is also suitable for arrayed studies for high-throughput, complex phenotypic analysis.
The Edit-R CRISPRa portfolio includes genome-wide, pre-designed guide RNAs for human and mouse, as either a lentiviral expression plasmid, lentiviral particles, or a two-part synthetic guide RNA. The system further utilizes nuclease-deactivated Cas9 fused to three activation domains provided as lentiviral particles or purified plasmids.